---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000110"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:58:46.192983+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris Q2 revenue $38.0M record, up 50% YoY; tightens FY23 guidance upward

## Summary
- Record total revenue $38.0M, QoQ +14%, YoY +50%; product revenue $36.9M (+46%).
- Gvoke net revenue $15.6M (+36%), Keveyis $14.1M (+10%), Recorlev $7.2M.
- FY23 revenue guidance tightened to $145M-165M from $135M-165M; cash utilization reduced to $57M-67M.
- Cash, equivalents and short-term investments $80.7M at June 30; on track for cash flow breakeven by year-end.
- Net loss $19.8M ($0.14 per share); Phase 2 study of XP-8121 (levothyroxine) began dosing.

## SEC filing metadata
- accession: 0001867096-23-000110
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/0001867096-23-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/xers-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000110
- JSON: https://secwatch.observer/filing/0001867096-23-000110.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000110.txt

## Key facts
- Earnings Releases
  Xeris Biopharma Holdings, Inc. reported full-year 2023 results: revenue $145 million to $165 million. Guidance raised.
  - Period: full-year 2023
  - Revenue: $145 million to $165 million
  - Guidance: raised
  - Result: guidance update
  source text: performance, and expectations for the remainder of the year gives us the confidence to tighten our 2023 guidance by raising the low end of the total revenue range to $145 to $165 million from $135 to $165 million; reducing cash utilization range to $57 to $67 million from $57 to $77 million; improving year-end cash range to $55 to $65 million. And, we expect to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/0001867096-23-000110-index.htm
- Earnings Releases
  Xeris Biopharma Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue $38.0M, net income $19.8 million, or $0.14 per share, EPS $0.14 per share. Guidance raised.
  - Period: the three and six months ended June 30, 2023
  - Revenue: $38.0M
  - Net income: $19.8 million, or $0.14 per share
  - EPS: $0.14 per share
  - Guidance: raised
  - Result: reported results
  source text: expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- XERIS BIOPHARMA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash equivalents and short-term investments Tightens
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/0001867096-23-000110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.